Healthcare

Quest Diagnostics runs one of the largest U.S. lab networks, serving physicians, hospitals, employers, and patients. Recent growth has improved, cash flow has recovered, and margins remain stronger than much of healthcare, giving the company a solid defensive profile.

CSL is a global biotech leader in plasma therapies, flu vaccines, and iron deficiency treatments. The business combines resilient healthcare demand, strong cash generation, and hard-to-replicate infrastructure, while a lower valuation now puts unusual focus on earnings quality.

Cencora is a global pharmaceutical distributor that plays a critical role in getting medicines to pharmacies, hospitals, and care providers. Its scale, specialty-drug exposure, and strong cash generation make it a compelling company to examine for long-term market exposure.

Centene is a major U.S. managed-care company centered on Medicaid and Marketplace coverage. Its scale, broad state footprint, and strong cash generation make it notable, while the key question is whether profitability can recover enough to match the reach of the franchise.

Cigna is a healthcare giant combining insurance with pharmacy benefit management and care services. Strong cash generation, large scale, and durable healthcare demand make it an interesting company to examine, especially as its valuation remains restrained.

Alnylam is one of the clearest commercial leaders in RNA interference medicine, with fast revenue growth, rising profitability, and multiple approved therapies. Its appeal rests on turning a proven gene-silencing platform into larger markets beyond rare disease.

Boston Scientific sells medical devices used in minimally invasive procedures across cardiology, endoscopy, urology, rhythm management, and neuromodulation. Rising cash flow, stronger margins, and exposure to durable healthcare demand make its long-term profile worth a closer look.